KRAS plays an important role in driving glycolysis in pancreatic cancer, leading to progression of the disease by increasing GLUT1, hexokinase II (HK II), and phosphofructokinase 1 (PFK1) expression (151–154). Here, PFKM is linked to pancreatic neoplasm.